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Abstract
Background—Antiretroviral drugs are used for the treatment and prevention of HIV infection.
Non-adherence to antiretroviral drug regimens can compromise their clinical efficacy and lead to
emergence of drug-resistant HIV. Clinical trials evaluating antiretroviral regimens for HIV
treatment and prevention can also be compromised by poor adherence and non-disclosed off-study
antiretroviral drug use. This report describes the development and validation of a high throughput,
qualitative method for the identification of antiretroviral drugs using high-resolution mass
spectrometry (HRMS) for the retrospective assessment of off-study antiretroviral drug use and the
determination of potential antiretroviral therapy (ART) non-compliance.
Methods—Serum standards were prepared that contained 15 antiretroviral drugs: 9 protease
inhibitors (PIs), 4 nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), and 2
nonnucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs). Analytical separation was
achieved on a Hypersil Gold PFP (100 × 3 mm) column and the eluent was analyzed using the
Thermo Exactive Orbitrap mass spectrometer (Exactive-MS) operated in full scan mode. Limit of
identification, signal intensity precision, retention time analysis, selectivity, and carryover studies
were conducted. Concordance with liquid chromatographic-tandem mass spectrometric (LC-
MS/MS) methods was evaluated using remnant plasma samples from a clinical trial.
Results—The limit of identification ranged from 5-10 ng/ml for 14 drugs (9 PIs, 1 NNRTI, 4
NRTIs) and was 150 ng/ml for 1 NNRTI. Precision studies with high and low control mixtures
revealed signal intensity coefficients of variation of 3.0-27.5%. The Exactive-MS method was
© 2014 Elsevier B.V. All rights reserved.
*Corresponding author information: Department of Pathology, The Johns Hopkins University School of Medicine, 1800 Orleans
St., Sheikh Zayed Tower, B1-1020F, Baltimore, MD 21287, USA. Tel: +1 410 502 7692; fax: +1 410 955 0767. address:
wclarke@jhmi.edu (W. Clarke)..
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Clin Chim Acta. Author manuscript; available in PMC 2015 June 10.
Published in final edited form as:
Clin Chim Acta. 2014 June 10; 433: 157–168. doi:10.1016/j.cca.2014.03.016.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
selective for the compounds of interest. Overall, concordance ranged from 89.1%-100% for the
screening of antiretroviral drugs in clinical plasma specimens as compared to LC-MS/MS
methods.
Conclusion—Using the Exactive-MS, we developed and validated a highly selective, robust
method for the multiplexed detection of 15 antiretroviral drugs.
Keywords
antiretroviral; clinical trials; high-resolution mass spectrometry; Exactive-MS; validation
1.0 Introduction
An estimated 34 million people are living with human immunodeficiency virus/acquired
immune deficiency syndrome (HIV/AIDS) worldwide, with approximately 2.5 million new
infections occurring annually [1]. Numerous antiretroviral drugs are approved for HIV
treatment by the United States Food and Drug Administration (FDA) in single drug and
multi-drug formulations [2]. The most widely used classes of antiretroviral drugs are
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) [3,4]. Antiretroviral drugs
were first introduced in the late-1980s; however, subsequent research demonstrated that
potent, multi-drug regimens are needed for durable suppression of viral replication and
clinical benefit [3]. Most antiretroviral treatment regimens include two NRTIs with an
NNRTI or PI [4,5]. Newer classes of antiretroviral drugs include entry inhibitors, fusion
inhibitors, and integrase inhibitors [6,7].
While antiretroviral drugs are effective for treatment of HIV infection, non-adherence to
treatment regimens can lead to treatment failure and emergence of drug-resistant HIV strains
[8,9]. Adherence counseling is an important component of HIV treatment. However, the
complexity of treatment regimens, adverse events, and other factors can reduce adherence
[9,10]. Antiretroviral drugs are also used for HIV prevention in a variety of settings,
including prevention of mother-to-child transmission, pre-exposure prophylaxis in HIV-
uninfected individuals (PrEP), and “treatment for prevention” in HIV-infected individuals
[11-13]. A variety of approaches have been used for adherence monitoring in clinical trial
settings (e.g., self-report, pill counts, electronic monitoring, monitoring pharmacy refills);
however, each of these approaches has limitations [14,15]. Furthermore, some participants
in clinical trials may not disclose that they are using antiretroviral drugs provided outside of
the study [16,17]. For example, in the HIV Prevention Trials Network (HPTN) 052 study
[18], some HIV-infected participants who reported that they were antiretroviral drug naïve at
study enrollment had antiretroviral drugs detected in their blood that indicated that they were
on antiretroviral treatment [17].
The limitations of self-report and other approaches used for adherence monitoring highlight
the need for rapid, high-throughput methods that can be used for the direct detection of
antiretroviral drugs in clinical and research settings. Several methods are available for the
quantification of a single antiretroviral agent in plasma. The majority of these approaches
involve liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis in
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selected reaction monitoring (SRM) mode. However, since antiretroviral regimens almost
always include a combination of drugs, and since study participants may access a variety of
antiretroviral medications outside of clinical trials, laboratory methods are needed that can
detect a large number of antiretroviral drugs, ideally in a single analytical run. To address
this need, sensitive methods have been developed for simultaneous quantification of 12-18
drugs (including PIs, NRTIs, and NNRTIs) in a single chromatographic run using LC-
MS/MS techniques [19-21]. However, those methods may not include newer antiretroviral
drugs [19,20]. Further, while SRM-based quantitative analysis is useful for pharmacokinetic
studies, qualitative, multiplexed methods may be more suitable for evaluation of non-
compliance or off-study use of antiretroviral drugs, similar to qualitative methods used for
monitoring pain management regimens, as well as drugs of abuse. With existing challenges
to antiretroviral therapy (ART) adherence, including healthcare systems and socioeconomic
factors, qualitative identification of drugs to assess compliance is warranted [22].
Therapeutic drug monitoring of antiretroviral classes is dependent on inter-individual
pharmacokinetic variability, as well as the identification of a range that discriminates a
therapeutic drug concentration from a toxic concentration. Because the treatment of HIV
infection requires multi-drug regimens that may act antagonistically or synergistically, and
several collections may be needed to understand the pharmacokinetic parameters of the
drug, routine quantitative monitoring of antiretroviral drugs is not commonly performed
[23].
Many methods currently available for drug monitoring use a triple quadrupole mass analyzer
operated in SRM mode. In this report, we exploit high-resolution mass spectrometry
(HRMS) for qualitative drug detection; HRMS has previously been pursued for the
identification of other compounds in biological matrices [24-28]. An advantage of this
approach is that instruments used for HRMS may be operated in a full scan mode, in which
all ions are detected and analyzed by the mass spectrometer. A major benefit of using
HRMS for antiretroviral drug detection is that sample data may be retrospectively analyzed
for analytes that were not part of the initial screening assessment (e.g., other antiretroviral
drugs, substances of abuse); this increases the flexibility of data collection and review.
Current analyzers that offer high resolution accurate mass determination include time of
flight (TOF) instruments, as well as instruments using Orbitrap technology. The Orbitrap
consists of an outer barrel-like electrode and a co-axial central electrode; ions within the
Orbitrap oscillate around this central electrode [29]. Mass to charge ratios are measured
from the frequency of harmonic ion oscillations around this central electrode along the axis
of the electrostatic field [29, 30]. The frequency of these oscillations are detected and
transformed into mass spectra via Fourier-transformation [29]. The Orbitrap offers high
mass accuracy set at thresholds of ± 5 ppm of theoretical mass values [29]. Currently, the
Thermo Exactive mass spectrometer (Exactive-MS) uses the Orbitrap for HRMS; the
Exactive-MS also contains a higher-energy collision cell, in which trapped ions may be
subjected to high-energy collision-induced dissociation potentials, generating fragment ions
[31]. Fragmentation may also occur at the ionization source through the application of
increased voltage. The work described in this report uses the Exactive-MS for the
development, validation and application of a method for the retrospective, simultaneous,
qualitative detection of 15 antiretroviral agents used for HIV treatment and prevention.
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2.0 Experimental
2.1 Chemicals
The antiretroviral agents monitored by this method include PIs [amprenavir (APV),
atazanavir (ATV), darunavir (DRV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV),
ritonavir (RTV), saquinavir (SQV) and tipranavir (TPV)]; NRTIs [emtricitabine (FTC),
lamivudine (3TC), tenofovir (TFV) and zidovudine (ZDV)]; and NNRTIs [efavirenz (EFV)
and nevirapine (NVP)]. These drugs were obtained as stock powder solutions through the
AIDS Research and Reference Reagent Program (Pathogenesis and Basic Research Branch,
Division of AIDS, NIAID, NIH; https://www.aidsreagent.org/index.cfm). Stock solutions
were reconstituted in methanol or water (TFV and ZDV), depending on solubility, to master
stock concentrations of 1 or 2 mg/ml. To ensure proper sample preparation and Exactive-MS
analysis, an external reference molecule (morphine-D3, Toronto Research Chemicals, North
York, ON) was included. Drug-free human serum was acquired from BioRad Laboratories
(Irvine, CA). Formic acid was from Sigma-Aldrich. Drug-free human K2 EDTA plasma was
acquired from Bioreclamation. Acetonitrile, acetone and methanol (all Optima-grade), and
high performance liquid chromatography (HPLC)-grade water were from Fisher Scientific.
HPLC-grade isopropanol was rom JT Baker.
2.2 Preparation of Reagents and Standards
To identify the specific retention times and fragmentation patterns for each analyte, working
stock solutions were prepared from master stocks to final concentrations of 100 µg/ml and
10 µg/ml in 1:1 methanol:water. For each analyte, diluted stocks (1,000, 500, 250, 150, 100,
50, 25, 10 and 5 ng/ml) were prepared by spiking human serum with appropriate volumes
from working solutions. After determining analyte-specific retention times and confirmation
of fragment ions, when applicable, the 15 antiretroviral agents were combined from master
stock solutions and prepared to the aforementioned final concentrations by spiking human
serum or K2 EDTA plasma with appropriate volumes from combined working solutions. A
standard mixture of morphine-d3 was prepared in acetonitrile at a final concentration of 125
ng/ml. Sample preparation involved combining 100 μl of spiked serum or subject specimen
with 300 μl of acetonitrile containing morphine-d3, an easily-ionized species that was used
to assess processing and analytical integrity of a specimen. The mixture was then briefly
vortexed and centrifuged at 12,000 × g for 5 min at room temperature. Entire supernatants
were evaporated to dryness using a Biotage SPE Dry 96 well plate dryer with the application
of constant airflow, and subsequently reconstituted in 150 μl water; 30 μl of reconstituted
samples were subjected to chromatographic separation.
2.3 Instrument and Acquisition Parameters
The liquid chromatography system consisted of an Aria TLX1 system (Thermo Fisher
Scientific) equipped with a CTC HTC PAL Autosampler with a sample stack maintained at
4°C and 2 Transcend pumps. The TLX1 chromatography system was also configured with
two 6-port switching valves controlled by the Aria OS software (Thermo Fisher). The
autosampler was programmed to inject 30 μl of sample into the TLX1 system. Analytical
separation was achieved using the Thermo Scientific Hypersil Gold PFP, 100 × 3 mm
column, with a 3 μm particle size (Thermo Fisher). Mobile phase A consisted of water with
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0.1% acetic acid, while mobile phase B consisted of acetonitrile with 0.1% acetic acid. The
chromatographic run began with 30 sec of mobile phase A, followed by a 60 sec ramp to
10% mobile phase B. This slow ramp facilitated the elution of water-soluble analytes. The
chromatographic separation continued with a step to 15% mobile phase B followed by a
ramp to 95% mobile phase B over 600 seconds. Following the elution of all analytes, the
column was washed for 60 sec with a 2:2:1 ratio of isopropanol:acetonitrile:acetone. The
column was then re-equilibrated for 180 sec with mobile phase A. The total analytical run
time for this method is 16.0 minutes and occurs at a flow rate of 500 μl/minute.
Detection of antiretroviral agents was performed using the Exactive-MS (Thermo Fisher)
with a heated electrospray-ionization source in positive ionization mode and full scan mode.
The Exactive-MS method included two scan events in positive polarity: one full scan event
with ultra-high resolution (100000 @ 1Hz) and an additional scan event with in-source
collision-induced dissociation (SCID) at 45eV with enhanced resolution (25000 @ 4Hz). All
scan events were programmed for 100 msec maximum injection time and balanced
automatic gain control (AGC) intensity targets. Additionally, instrument parameters were
optimized, including sheath gas flow rate (20), discharge current (5 μA), capillary
temperature (250°C), capillary voltage (10 V), tube lens voltage (140 V), skimmer voltage
(12 V) and vaporizer temperature (250°C), through the analysis of an extracted 500 ng/ml
ARV mixture prepared in serum. Since this method includes a variety of structurally
dissimilar compounds, the mass spectrometer parameters identified as optimal were based
on the highest signal intensity and fragment identification for analytes of interest. The
aforementioned parameters were optimal for protease inhibitors, as well as several NRTIs
and NNRTIs, including 3TC and FTC (NRTIs), and NVP (NNRTI). Antiretroviral
molecular structures, precursor ion m/z ([M+H+]), and monitored fragments, when
applicable, are described in Table 1.
2.4 Data Evaluation
Data analysis included automated review using the ToxID 2.1.1 and Xcalibur 2.2 programs
(Thermo Fisher). Using the ToxID 2.1.1 data review software package, antiretroviral drug
detection was evaluated in an automated manner, based on the presence of exact mass (± 5
ppm from theoretical mass), retention time (± 0.4 min from control standards), and the
presence of fragments (with the exception of EFV, in which no fragment ions were
observed). The presence of fragments was based on the identification of a fragment ion with
an exact mass (±5 ppm from theoretical mass) as well as the identification of the fragment at
the same retention time as the precursor drug. It should be noted that while signal intensity
was not used as a specific acceptance criteria, identified fragments yielded signal intensities
approximately one order of magnitude lower than the intensity observed for the precursor
compound. Signal intensity thresholds were based on validation metrics, including limit of
identification and carryover studies.
Fragment prediction was determined using the MassFrontier 7.0 (Thermo Fisher) prediction
utility, which determines fragmentation based on theoretical models, as well as fragments
based on a software-provided library containing known published fragmentation data. While
alternative approaches, including the direct infusion of a neat mixture of an ARV agent,
Marzinke et al. Page 5
Clin Chim Acta. Author manuscript; available in PMC 2015 June 10.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
could also be used to empirically select for fragment ions, prediction software was employed
to identify species that result from fragmentation at susceptible chemical bonds and
particular structural moieties. This approach avoids the inclusion of fragments based on
potential adducts or fragments formed through secondary decompositions involving
randomized rearrangements, which do not denote specific structural moieties, thereby
reducing the reporting of falsely positive results. Predicted fragments were confirmed via
spectral deconvolution, in which the ion spectra from the higher energy in-source CID scan
event were evaluated for the presence of predicted fragment ions.
Potential positives for EFV and ZDV, which did not consistently elicit fragments, were
manually confirmed using the XCalibur 2.2 software. The presence of the analyte at the
correct retention time (± 0.4 min) was assessed using post-processing mass filters with a ± 5
ppm threshold from theoretical mass. This manual review was performed for EFV because
no fragment ion was identified, and for ZDV because fragmentation was not observed at
concentrations <50 ng/ml.
3.0 Method Validation
The validation metrics assessed for this qualitative method included: analyte signal and
retention time within-run precision, limit of identification, carryover, selectivity, and method
concordance studies.
3.1 Precision
Within-run precision was evaluated for each analyte when standards were run five times
within a single run as: (1) a high control mixture containing 1000 ng/ml of all analytes, and
(2) a low control mixture containing 400 ng/ml of EFV and 50 ng/ml of the remaining 14
analytes. Mean signal intensities and retention times, as well as standard deviations (SD) and
coefficients of variation (% CV), were assessed at each level. Within-run precision studies
were also conducted for the morphine-d3 external reference molecule.
3.2 Limit of Identification and Carryover Analysis
For limit of identification (sensitivity) studies, antiretroviral agents were prepared at the
aforementioned concentrations in drug-free human serum. The limit of identification was
based on the lowest concentration at which a precursor ion was observed using a ± 5 ppm
threshold from theoretical mass, retention time, and the presence of fragments. Notable
exceptions for fragment identification include EFV at all analyzed concentrations, and ZDV
at concentrations <50 ng/ml. The limit of identification was further established by
comparing the signal intensity threshold of the lowest concentration that met the
aforementioned criteria with a post-injection serum blank following an extracted specimen
containing a 2.5 μg/ml mixture of the 15 antiretroviral agents.
Further, to illustrate comparability between plasma and serum matrices, ARV mixtures were
spiked into drug-free human plasma to yield final concentrations of 1,000, 500, 250, 150,
100, 50, 25, 10 and 5 ng/ml of each antiretroviral drug. Samples were extracted as
previously described and analyzed in parallel with serum-spiked specimens at the
aforementioned concentrations. Samples were analyzed in triplicate and observed mean
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analyte peak areas, as well as SDs and %CVs were calculated across each level. Further, a %
difference was determined by calculating the difference between the plasma-spiked mixture
and the serum-spiked mixture, divided by the serum-spiked mixture, and multiplied by 100.
3.3 Selectivity
To assess assay selectivity, five specimens free of antiretroviral agents were extracted as
previously described. Results were reviewed using both the automated ToxID 2.1.1 and
manual Xcalibur 2.2 software modules. Additionally, a 250 ng/ml ARV mixture was spiked
into a series of solutions containing varying levels of bilirubin, hemoglobin, and lipids.
Samples were extracted in triplicate and analyzed using the Exactive-MS method. A
significant interference was determined as a decrease in peak area for an ARV drug >50% as
compared to analyte peak area spiked into a solution with no interferent present. Sample
indeces were determined on a cobas® series analyzer (Roche Diagnostics).
3.4 Method Comparison
Sixty-four plasma specimens were obtained from the HIV Trials Prevention Network
(HPTN) 052 study [18]. These specimens were previously analyzed by the Clinical
Pharmacology Analytical Laboratory (Division of Clinical Pharmacology, Johns Hopkins
University School of Medicine) [17]. The previous analysis involved 3 LC-MS/MS methods
(3 separate assays) using a triple quadrupole mass analyzer. One LC-MS/MS method
identified the following analytes (PIs and NNRTIs) with a cutoff of 100 ng/ml: APV, ATV,
DRV, EFV, IDV, LPV, NFV, RTV, SQV and TPV; a second LC-MS/MS method detected
the NRTI 3TC and the NNRTI NVP, with a limit of identification of 20 ng/ml; a third LC-
MS/MS method detected the NRTIs FTC, TFV, and ZDV with a limit of identification of 5
ng/ml. In this study, these plasma specimens were analyzed in a blinded manner using the
qualitative, Exactive-MS method described above. Overall concordance between the two
approaches was determined as the number of specimens that showed agreement based on the
limits of identification for the Exactive-MS and the LC-MS/MS methods.
4.0 Results and Discussion
4.1 Full-Scan Ion Acquisition
In this work, the Exactive-MS was used for the qualitative monitoring of 15 antiretroviral
agents. The described method was developed to retrospectively test blood specimens for off-
study use of antiretroviral drugs in a clinical study, and may be applied to assess ART non-
compliance. The Exactive-MS was operated in full scan mode, with two positive scan
events. A representative total ion chromatogram of antiretroviral agents spiked into drug-
free human serum is shown in Fig. 1. Since all ions are recorded using this approach, the
Exactive-MS allows for the retrospective detection of analytes of interest. This non-targeted
ion collection offers enhanced flexibility for post-hoc data analysis and specimen querying.
HRMS has been used in the analysis and detection of synthetic cannabinoids, as well as
organic pollutants and drugs of abuse [25-28,32,33,34]. By extension, study specimens
analyzed for the presence of antiretroviral agents could also be retrospectively queried for
other compounds (e.g., substances of abuse). The developed method was designed for the
rapid and robust identification of antiretroviral drugs in a qualitative manner. Targeted
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quantitative analyses could be performed using SRM-based LC-MS/MS methods with the
inclusion of an isotopically-labeled internal standard or structural analog.
4.2 Analyte Identification Criteria
Antiretroviral agent detection in the raw data form was based on expected retention time,
mass accuracy, and the presence of at least one fragment ion, with the exceptions of EFV
and ZDV concentrations <50 ng/ml. Analyte detection was based on strict mass accuracy (±
5 ppm) and retention time (± 0.4 min) tolerance thresholds. These tolerance thresholds have
been previously described and implemented in the qualitative monitoring of large panels of
molecules using HRMS [25, 35]. The retention time and mass accuracy thresholds provide
high selectivity in antiretroviral identification and reduce the probability of reporting false
positives. An external reference molecule (morphine-d3) was added during initial protein
precipitation, to monitor sample and analytical quality. This approach has been utilized in
previously reported Exactive-MS methods [36,37].
Retention time windows were determined via the analysis of each antiretroviral agent
individually on the Exactive-MS. Using the Xcalibur 2.2 software, retention time and mass
filters were applied to view ion spectra and chromatograms, respectively. Fragment ions for
the 15 ARVs, with the exception of EFV, were determined using the fragment prediction
module of MassFrontier version 7.0; fragment ions were confirmed via spectral
deconvolution (described in the methods section, Table 1). For each protonated molecular
species, [M+H+], a mass filter was applied with a mass accuracy tolerance of (± 5 ppm)
from theoretical mass. Using parameters offered by the Xcalibur 2.2 software module, ion
spectra were reviewed to identify fragment ions across the scanning range of the precursor
peak. Fragment ion generation was achieved via the incorporation of an enhanced resolution
scan event performed during in-source collision-induced dissociation (SCID). The fragment
ions used for antiretroviral identification are consistent with fragment ions observed in the
literature.
An example of ion spectra and mass filtering for the PI, RTV, ritonavir (RTV) and the
NRTI, 3TC, are depicted in Fig. 2 and Fig. 3, respectively. Using the aforementioned
thresholds, ion spectral analysis for RTV (CH37H48N6O5S2) depicts the [M+H+] protonated
species at 8.73 minutes (Fig. 2A). Analysis for abundant fragment ions at that retention time
in the 45 eV SCID scanning event depicts two well- characterized fragment ions of RTV
(Fig. 2B) [38]. Applying the appropriate mass filters to the total ion chromatogram indicates
the presence of the precursor RTV molecule at 8.73 minutes, as well as the two fragment
peaks (Fig. 2C). It should be noted that the configurations of these fragments is tentative,
and based on the predicted cleavage of structural moieties; however, the aforementioned
fragment ions, at m/z 268 and m/z 296, have been previously used for both RTV
identification as well as quantification [38]. This approach is also depicted for the NRTI
3TC (Fig. 3A-3C) [39,40]. While many LC-MS/MS methods indicate a 3TC fragment at m/z
112, our mass spectrometric methods indicate the highest abundance ion was detected at m/z
95 across tested concentrations [40,41].
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4.3 Limit of Identification Analysis
Following the establishment of retention time thresholds and fragment ion identification, the
Exactive-MS method was evaluated for selectivity, limit of identification, precision and
carryover. Selectivity was assessed through the analysis of 5 antiretroviral-negative remnant
serum samples. No antiretroviral drugs were detected in the 5 specimens (data not shown),
indicating the selectivity of the high resolution accurate mass thresholds and retention time
windows for the qualitative detection of antiretroviral agents.
Limit of identification (sensitivity) analysis was determined as the lowest concentration for
each analyte at which the previously described identification criteria were met: ±5 ppm
accuracy from theoretical mass, retention time ± 0.4 minutes, and identification of at least
one fragment ion. The limits of identification for the protease inhibitors APV, ATV, IDV,
LPV, NFV, RTV, SQV, TPV, the NRTI 3TC and the NNRTI NVP were 5 ng/ml. The limits
of identification for the NRTIs FTC, TFV and ZDV and the PI DRV were 10 ng/ml. Lastly,
the limit of identification for the NNRTI EFV was 150 ng/ml. All antiretroviral agents were
detected in positive ionization mode. Due to the structural disparities between antiretroviral
compound classes, analytical separation and analyte ionization was optimized for the
majority of analytes. Consequently, TFV fragmentation was not observed <10 ng/ml and
ZDV fragmentation was not observed <50 ng/ml. In addition to studies in serum,
comparison studies were performed in drug-free plasma. There were no significant changes
observed with regard to the limit of identification of the analytes across the aforementioned
tested concentrations (data not shown). A comparison of coefficients of variation for serum
and plasma-prepared samples, as well as the percent difference between matrices is
demonstrated for the NRTI FTC in Supplemental Table 1. Based on these data, although
serum prepared solutions were analyzed for validation metrics, plasma samples may be
evaluated using the described method.
Traditional mass spectrometric methods identify the NNRTI EFV in negative ionization
mode, largely due to the presence of a highly electronegative CF3 constituent (Table 1) [42].
However, consistent with previously published observations, analyte detection in negative
ionization mode significantly impacted overall peak shape and sensitivity of the NRTI TFV
[43]. Notably, negative ionization mode significantly compromised the generation of the
well-characterized TFV fragment ion, which lacks a phosphomethoxy group, and has a mass
to charge ratio of m/z 176.0923 [43]. Therefore, the described Exactive-MS method was
operated in positive ionization mode. A driving factor in the rationale to optimize the
method for TFV is because TFV is commonly used for HIV treatment [5,44] and co-
formulated TFV plus FTC (marketed as Truvada®, Gilead Sciences) has been shown to be
effective for PrEP in some settings [13]. Further, pharmacokinetic analyses of these drugs
indicate a five to ten-fold increase in the steady state concentration of EFV compared to
TFV when administered at fixed doses [45,46]. Thus, a 150 ng/ml cutoff was deemed
acceptable for the qualitative monitoring of EFV.
4.4 Precision and Carryover Studies
Precision studies were performed on both high (1000 ng/ml all compounds) and low (400
ng/ml EFV and 50 ng/ml all other drugs) mixtures of antiretroviral agents spiked in human
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serum (Table 2). For signal intensity, % CVs ranged from 3.0-20.6% for the high control
mixture and from 3.0-27.5% for the low control mixture. Across both low and high control
mixtures, very little deviation was observed from expected retention times, with a maximum
% CV of 2.6%. A full analysis of signal intensity and retention time precision is described in
Table 2. It is notable that the highest variability in signal intensity was observed at 50 ng/ml
of ZDV, ranging from 2456-5059 in raw signal values. However, due to the high mass
accuracy thresholds, there was negligible noise, facilitating the qualitative identification of
an antiretroviral drug at lower analyte concentrations. Isotopically-labeled morphine was
added to each specimen during the sample preparation step at a concentration of 125 ng/ml.
Across 10 injections, the signal intensity and retention time % CVs were 2% and 1%,
respectively (data not shown). Upon characterization of retention time and signal thresholds,
the identification of all analytes, with the exceptions of the NRTI ZDV and the NNRTI
EFV, was conducted using automated peak review via the ToxID 2.1.1 software module
(Supplemental Table 2 and Supplemental Fig. 1).
Carryover analysis was performed by preparing a mixture containing 2.5 μg/ml of the
antiretroviral samples spiked in drug-free human serum and analyzing a post-injection
unspiked specimen. Using the automated peak detection module, a post-injection blank did
not identify any of the antiretroviral agents with the previously described signal intensity
settings (Supplemental Table 2 and data not shown). Further, the potential impact of excess
hemoglobin, lipids, or bilirubin on analyte ionization and detection was assessed. Evaluation
of analyte peak areas were performed in solutions containing varying levels of the
aforementioned interferents. None of the monitored ARVs were significantly impacted by
increased hemolysis or icterus up to indeces of 200 and 30 units, respectively. However,
several protease inhibitors, including ATV, IDV, LPV, NFV, RTV, SQV and TPV were
impacted by increased lipemia. Modest lipemia (L-index greater than 150 units) resulted in
decreased analyte peak area for LPV, NFV, RTV and SQV, while gross lipemia (L-index
greater than 300 units) impacted the detection of ATV, IDV and TPV (data not shown).
These data support the benefit of assessing specimen quality prior to analysis.
4.5 Concordance Analysis
The Exactive-MS method described above was used to screen for the presence of
antiretroviral agents in human plasma samples from the HPTN 052 study, a Phase III
randomized trial to assess treatment strategies for preventing the sexual transmission of HIV
in serodiscordant couples [17,18]. Plasma specimens from individuals who were reportedly
antiretroviral drug naïve and were not on study-administered treatment were previously
identified using LC-MS/MS methods [18]. The purpose of that study was to detect
undisclosed off-study antiretroviral drug use by study participants. To detect all of the
antiretroviral agents included in that sample panel, three separate LC-MS/MS methods were
required (see Method Comparison section of Experimental). A subset of the HPTN 052
specimens (n=64) was analyzed using the combined, qualitative, Exactive-MS method
described in this report.
Of the 15 antiretroviral agents monitored in the Exactive-MS method, 7 PIs (APV, DRV,
IDV, LPV, NFV, SQV and TPV) were not detected in any of the samples by any of the
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methods (data not shown); the aforementioned drugs were not commonly used in the
countries at the time of the study. It should be noted that samples used for analysis reflect
remnant specimens from a large international trial, which includes 13 study sites across 11
counties, and are reflective of a heterogeneous population. Acquiring a sufficient sample set
for the additional PIs was not feasible for the method concordance using the HPTN 052
sample cohort. The percent agreement, which was used as a measure of concordance, ranged
from 89.1% (for zidovudine) to 100% (ATV, FTC, EFV; Table 3). It should be noted that
while the Exactive-MS method was compared to LC-MS/MS methods, the LC-MS/MS
methods are still qualitative, and do not include isotopically-labeled standards for all of the
monitored compounds. While the triple quadrupole mass analyzers were operated in SRM
mode, the selection of fragment ions and overall identification criteria may be disparate
from the Exactive-MS identification conditions. Consequently, we were unable to provide
sensitivity and specificity metrics to the described Exactive-MS method, and thus report
overall agreement with another qualitative LCMS/MS approach for ARV identification.
Of note, for analytes in which there was not 100% agreement, this may be explained by the
differing limits of identification for specific ARVs. For example, one specimen screened
positive for NVP and one sample screened positive for RTV by Exactive-MS while both
samples were negative for the respective drugs by LC-MS/MS, which is consistent with the
lower limits of identification of the Exactive-MS method for NVP and RTV detection.
Further, the agreement for ZDV identification was 89.1%, which was the lowest of the 8
analytes detected by either method. While the limit of identification of ZDV by Exactive-
MS is 10 ng/ml, a fragment ion is not observed at concentrations <50 ng/ml. The LC-
MS/MS method has a limit of identification of 5 ng/ml and includes a structural analog of
ZDV (azidouridine), resulting in increased selectivity [17]. The increased selectivity and
more sensitive limit of identification criteria for ZDV by the LC-MS/MS method likely
explains the additional identification of ZDV in clinical plasma specimens.
Although several disparities between the Exactive-MS and LC-MS/MS methods could be
explained by the limits of identification of the respective methods, there were two samples
in which a lack of concordance could not be explained by assay limits of identification.
Specifically, 2 specimens were screened as positive for 3TC and NVP by the LC-MS/MS
methods, but not by Exactive-MS. This could be the result of a false positive by LC-
MS/MS, or the inability of the samples to meet all acceptance criteria for compound
identification. Upon further review of the specimens in question, it was noted that there was
only a limited amount of sample available for testing, so a question of freeze-thaw stability
and sample integrity may also explain the discrepancy, as the samples were analyzed by
Exactive-MS several months after LC-MS/MS analysis. However, during this time, samples
were maintained at -80°C for long-term storage.
While the Exactive-MS method offers the identification of a diverse set of compounds with
high mass accuracy (±5 ppm difference from theoretical mass), and can operate in full-scan
mode, the method has limitations. Technically, Exactive-MS is associated with slower scan
speeds as compared to triple quadrupole mass spectrometers, making it more difficult to
acquire ions in different scan modes [47]. Also, the Exactive-MS acquires all ions, and
because it is not operated in SRM mode, and all ions are collected, strict adherence to
Marzinke et al. Page 11
Clin Chim Acta. Author manuscript; available in PMC 2015 June 10.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
identification criteria, including both precursor and fragment retention time, and mass
accuracy, becomes paramount.
In clinical and research settings, self-report of adherence to antiretroviral regimens and off-
study antiretroviral use may be unreliable. Other methods for adherence monitoring also
have limitations [14, 15]. Direct detection of antiretroviral drugs in clinical samples or
research specimens may provide a more accurate picture of antiretroviral drug use. Since
routine monitoring of antiretroviral drugs via mass spectrometry is not performed to assess
adherence, defined cut-off concentrations for adherence are not known. However,
pharmacokinetic analyses show circulating plasma concentrations of antiretrovirals are
dependent upon drug interactions as well as specific therapeutic dosing formulations and
regimens. Further, defined definitions for adherence would require knowledge of time of
dose administration as well as time of collection, parameters which are not typically known.
5.0 Conclusions
This manuscript describes the development, validation and application of a robust, selective
Exactive-MS method for the qualitative monitoring of 15 antiretroviral agents in human
plasma. The method requires minimal sample pre-treatment, and based on the high mass
accuracy of the Exactive-MS, is selective and specific in the identification of a variety of
PIs, NRTIs and NNRTIs. The method also shows agreement LC-MS/MS qualitative assays.
Positive identification of an antiretroviral drug by the described Exactive-MS method could
be reflex-tested for identified drugs using quantitative SRM-based LC-MS/MS methods,
which would include the presence of an isotopically-labeled internal standard or structural
analog. A qualitative method for the identification of antiretroviral drugs facilitates the
monitoring of overall adherence to a therapeutic regimen, as well as potential off-study use.
Quantitative determination of a target drugs occurs to assess pharmacokinetic parameters,
including drug efficacy. This method could be used to monitor drug adherence in clinical
and research settings, and also to detect off-study antiretroviral drug use in clinical trials. A
major advantage of HRMS is that all ions are collected and monitored in a non-targeted
fashion, facilitating retrospective analysis and post-hoc data querying. Post-targeted data
analysis may have significant benefits in monitoring off-study antiretroviral drug use, as
well as re-querying data for other substances. Thus, the Exactive-MS method offers robust
and highly selective identification approaches for a diverse array of small molecules in a
non-targeted way.
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Highlights
• We use high-resolution mass spectrometry for antiretroviral drug identification.
• We show 96.7% concordance between HRMS and reference methods.
• The Exactive-MS method has limits of identification of 5-10 ng/ml for most
drugs.
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Fig. 1.
Total ion chromatogram from the Exactive-MS method collected in positive ionization
mode. Representative chromatogram of 1000 ng/ml antiretroviral mixture spiked into drug-
free human serum.
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Fig. 2.
Ion spectra of ritonavir generated by Exactive-MS (A) with the inclusion of an in-source
collision-induced dissociation scan event for fragment production and detection (B) . Based
on the m/z fragment ions monitored, we postulate that the m/z 268 and m/z 296 fragment
ions were formed through the cleavage of a keto-isopropyl linkage and an amide bond,
respectively. Retention time determination through the application of a mass filter with ± 5
ppm discrimination from theoretical mass of precursor and fragment ions (C).
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Fig. 3.
Ion spectra of lamivudine generated by Exactive-MS (A) with the inclusion of an in-source
collision-induced dissociation scan event for fragment production and detection (B) .The 95
m/z fragment ion was likely formed through the loss of the oxathiol moiety and subsequent
loss of a NH3 constituent. Retention time determination through the application of a mass
filter with ± 5 ppm discrimination from theoretical mass of precursor and fragment ions (C).
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Table 1
Antiretroviral agents monitored in Exactive-MS method.
Antiretroviral Agent Structure Molecualar Formula [M+H]+ (m/z) Fragment Ions
Protease Inhibitors
Amprenavir (APV) C25H35N3O6S 506.2319 245.1637
Atazanavir (ATV) C38H52N6O7 705.3970 335.1948
168.0801
Darunavir (DRV) C27H37N3O7S 548.2425 392.1989
69.0335
Indinavir (IDV) C36H47N5O4 614.3701 513.2847
465.2845
421.2339
Lopinavir (LPV) C37H48N4O5 629.3697 447.2621
183.1121
155.1172
Nelfinavir (NFV) C32H45N3O4S 568.3204 467.2342
330.1142
Ritonavir (RTV) C37H48N6O5S2 721.3200 296.1413
268.1465
Saquinavir (SQV) C38H50N6O5 671.3915 570.3052
433.1853
Tipranavir C31H33F3N2O5S 603.2135 585.1999
375.2175
333.1707
Nucleotide/Nucleoside Reverse Transcriptase Inibitors
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Antiretroviral Agent Structure Molecualar Formula [M+H]+ (m/z) Fragment Ions
Emtricitabine (FTC) C8H10FN3O3S 248.0500 130.0406
Lamivudine (3TC) C8H11N3O3S 230.0594 95.0237
Tenofovir (TFV) C9H14N5O4P 288.0856 176.0923
Zidovudine (ZDV) C10H13N5O4 268.1040 127.0497
Non-nucleoside Reverse Transcriptase Inhibitors
Efavirenz (EFV) C14H9ClF3NO2 316.0347 N/A
Nevirapine (NVP) C15H14N4O 267.1240 227.0924
226.0837
107.0599
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